Indivior Pharmaceuticals (INDV) vs Parabilis Medicines (PBLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Indivior Pharmaceuticals is the larger company by market cap ($4.18 billion vs $3.47 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDV | PBLS |
|---|---|---|
| Share price | $35.45 | $28.09 |
| Market cap | $4.18B | $3.47B |
| 1-day change | -1.88% | -2.53% |
| YTD return | -1.20% | — |
| 1-year return | +47.28% | — |
| 5-year return | +123.66% | — |
| P/E ratio (TTM) | 12.71 | — |
| Forward P/E | 7.26 | — |
| EPS (TTM) | $2.79 | $-9.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | — |
| Revenue growth (YoY) | +4.29% | — |
| Net income (latest FY) | $210.00M | — |
| Gross margin | 80.23% | — |
| Operating margin | 21.15% | — |
| Net margin | 16.95% | — |
| 52-week high | $42.81 | $42.49 |
| 52-week low | $22.95 | $24.51 |
| Distance from 52-week high | -17.19% | -33.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +38.22% | +48.63% |
| Average volume | 2.08M | 690.91K |
| Shares outstanding | 118.03M | 121.95M |
| Employees | 827 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
INDV vs PBLS FAQ
Which is bigger, Indivior Pharmaceuticals or Parabilis Medicines?
Indivior Pharmaceuticals (INDV) is larger, with a market capitalization of $4.18B compared with $3.47B for Parabilis Medicines (PBLS).
Are Indivior Pharmaceuticals and Parabilis Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.